Related Experiment Video
Updated: Jun 5, 2026
12:35
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)
Published on: March 17, 2012
Modelling progressive autonomic failure in MSA: where are we now?
Sylvia Stemberger1, Gregor K Wenning
1Division of Clinical Neurobiology, Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
Journal of Neural Transmission (Vienna, Austria : 1996)
|January 12, 2011
Summary
Developing preclinical models for Multiple System Atrophy (MSA) is crucial. Current research focuses on motor symptoms, but modeling autonomic failure (AF) in MSA requires further investigation in these models.
Area of Science:
- Neuroscience
- Neuropathology
Background:
- Multiple system atrophy (MSA) is a fatal neurodegenerative disease characterized by ataxia, Parkinsonism, and autonomic failure (AF).
- Preclinical models are essential for developing new treatments for MSA.
- Current models primarily focus on motor symptoms and associated neuropathology in the brainstem, cerebellum, and basal ganglia.
Purpose of the Study:
- To review the development of preclinical testbeds for Multiple System Atrophy (MSA).
- To highlight the limitations in modeling the prominent autonomic failure (AF) feature of MSA.
- To discuss emerging evidence of AF-like features in transgenic MSA models.
Main Methods:
- Review of existing preclinical models for MSA.
- Analysis of studies focusing on motor and autonomic features in MSA models.
- Examination of neuropathological findings in relevant brain regions.
Main Results:
- Most preclinical MSA models successfully replicate motor deficits and related neuropathology.
- Modeling progressive autonomic failure (AF) in MSA has been limited.
- Emerging evidence indicates that some transgenic MSA models exhibit AF-like features linked to α-synucleinopathy in autonomic networks.
Conclusions:
- Optimized preclinical models are needed to fully characterize both autonomic and motor features of MSA.
- Further research is required to validate and utilize models that capture the full spectrum of MSA pathology.
- Improved preclinical models will accelerate the development of effective interventional strategies for MSA.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:29Cardiomyopathy VI: Nursing Management
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...